Esperion Therapeutics (ESPR)
(Real Time Quote from BATS)
$1.80 USD
+0.18 (11.11%)
Updated Aug 6, 2025 11:12 AM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Esperion Therapeutics, Inc. has a PEG ratio of 0.84 compared to the Medical - Drugs industry's PEG ratio of 1.36.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ESPR 1.80 +0.18(11.11%)
Will ESPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?
Other News for ESPR
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ...
Esperion Therapeutics (ESPR) Sees Revenue Surge, Eyes Profitability by 2026
Q2 2025 Esperion Therapeutics Inc Earnings Call Transcript
Esperion rises after revenue beat, Q1 profitability expectation
Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues